Compare GWH & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWH | DARE |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 35.5M |
| IPO Year | N/A | 2014 |
| Metric | GWH | DARE |
|---|---|---|
| Price | $1.02 | $2.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $2.25 | ★ $10.00 |
| AVG Volume (30 Days) | 680.4K | ★ 784.9K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | $33.99 | $2,115.12 |
| Revenue Next Year | $1,328.57 | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.74 | $1.27 |
| 52 Week High | $13.87 | $9.19 |
| Indicator | GWH | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 45.56 |
| Support Level | $0.74 | $1.80 |
| Resistance Level | $1.22 | $2.54 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 74.61 | 24.15 |
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. It develops and manufactures long-duration energy storage systems based on iron flow battery technology. The company's batteries use earth-abundant materials, including iron, salt, and water, and are designed for high cycle life and recyclability. It operates as a single business operating segment, which includes all activities related to the design, engineering, and manufacturing of the company's long duration energy storage products. The company's revenue is derived from the sale of its energy storage products and from service contracts.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.